Recent Progress on the Molecular Aspects of Endocrine Tumors: Clinical Implications

Hormone Research in Paediatrics

Volumn 47, Issue 4-6, 1997, Pages 163-167

  Rouvier, Eric ^a   Emmanuel, Gautherot ^a   Meyer, Pascal ^a   Barbel, Jacques ^a  

^a Immunotech   (France)

Author keywords

Bispecific antibodies; Immunoscintigraphy; Medullary thyroid carcinoma

Indexed keywords

BISPECIFIC ANTIBODY; HAPTEN;

CANCER RECURRENCE; CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; IMMUNOSCINTIGRAPHY; ISOTOPE LABELING; META ANALYSIS; PRIORITY JOURNAL; THYROID MEDULLARY CARCINOMA; TUMOR CELL;

EID: 85025541054     PISSN: 16632818     EISSN: 16632826     Source Type: Journal    
DOI: 10.1159/000185460     Document Type: Article

References (31)

1. Block MA: Surgical treatment of medullary carcinoma of the thyroid, Otolaryngol Clin North Am 1990;23:453-473.
2. Molcy JF: Medullary thyroid cancer, Surg Clin North Am 1995;75:405-420.
3. Tubiana M, Milhaud G, Coutris G, Lacour J, Parmentier C, Bok B: Medullary carcinoma and thvrocalcitonin, BrMed.1 1968;4:87-89.
4. Goltzman D, Potts JT, Ridgway EC, Maloof F: Calcitonin as a tumor marker, Use of the radioimmunoassay for calcitonin in the postoperative evaluation of patients with medullary thyroid carcinoma, N Engl J Med 1974:290: 1035-1039.
5. Block MA, Lackson CE, Tashjian AH: Management of occult medullary thyroid carcinoma evidenced only by serum calcitonin level elevations after apparently adequate neck operations, Arch Surg 1978:113:368-372.
6. l3lI-meta-iodobenzvl guanidine, Nucl Med Com-mun 1986:7:215-221.
7. Clarke SE, Lazarus C, Mistry R- Maiscv MN: The role of tcchnetium-99m pentavalent DMSA in the management of patients with medullary carcinoma of the thyroid, Br J Radiol 1987:60:1089-1092.
8. Kwckkcboom DJ, Rcubi JC, Lamberts SW, Bruining HA, Mulder AH, Oci HY, Krenning EP: In vivo somatostatin receptor imaging in medullary thyroid carcinoma, J Clin Endocrinol Metab 1993;76:1413-1417.
9. Dorr U, Sautter-Bihl ML, Bihl H: The contribution of somatostatin receptor scintigraphy to the diagnosis of recurrent medullary carcinoma of the thyroid, Semin Oncol 1994;21:42-45.
10. Lumbroso J, Berche C, Mach JP, Rougier P, Aubrv F, Buchcgger F, Lasser P, Parmentier C, Tubiana M: Use of tomographic scintigraphy with radio-labelled monoclonal antibodies for detecting human digestive cancers and medullary' cancers of the thvroid, Bull Cancer (Paris) 1983;70:96-102.
11. 1111-labelled monoclonal anti-CEA antibody fragment, Nuklearmcdizin 1986:25:227-231.
12. WmTc-labelled anti-CEA monoclonal antibody for tumour immunoscin-tigraphy: First clinical results, Nucl Med Com-mun 1989;10:345-352.
13. 1 "In-labeled F(ab')j fragments of anticarcinoembryonic antigen monoclonal antibody for detecting recurrences of medullary thyroid carcinoma, J Clin Endocrinol Metab 1992;74:157-163.
14. Le Doussal JM, Chctanneau A, Guyon-Gruaz A, Martin M, Gautherot E, Lehur PA, Chatal JF, Delaage M, Barbet J: Bispecific monoclonal antibody-mediated targeting of an indium-111-labclcd DTPA dimer to primary colorectal tumors: Pharmacokinetics, biodistribution, scintigraphy and immune response, J Nucl Med 1993;34:1662-1671.
15. 11'In-labelled bivalent hapten and a bispecific antibody conjugate, Nucl Med Commun 1994;15:972-980.
16. Vuillez JP, Moro D, Brichon PY, Rouvier E, Brambilla E, Barbel J, Meyer P, Peltier P, Sarrazin R, Brambilla C: Two-step immunoscinti-graphy for non-small ccll lung canccr staging using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer, J Nucl Med, in press.
17. Peltier P, Curtct C, Chatal JF, Le Doussal JM, Daniel G, Aillct G, Gruaz-Guyon A, Barbet J, Delaage M: Radioimmunodetection of medullary thyroid canccr using a bispecific anti-CEA/ anti-indium-DTPA antibody and an indium-II 1-labeled DTPA dimer, J Nucl Med 1993; 34:1267-1273.
18. Barbet J, Peltier P, Bardet S, Vuillez JP, Ba-chelot I, Leccia F, Bordenavc L, Dcnet S, Olivier P, Huglo D, Prove C, Rouvicr E, Meyer P: Immunoseintigraphy of recurrent medullary thyroid carcinoma using a bispecific antibody and an indium-111-labeled bivalent hapten: A mullicenter study of 42 patients with elevated thyrocalcitonin blood levels (abstract), 42th Annu Meet SNM, Minneapolis, 1995.
19. Barbel J, Peltier P, Bardet S, Vuillez JP, Ba-chclot I, Denet S, Olivier P, Leccia F, Corcul Y B, Huglo D, Prove C, Rouvier E, Meyer P, Chatal JF: Radioimmunodetection of medullary thyroid carcinoma using a bispccific antibody and an indium-111-labeled bivalent hapten: A multiccntcr study of 44 patients with elevated calcitonin blood levels, submitted.
20. Gruaz-Guyon A, De Labriolle-Vaylet C, Wio-land M, Sarfati E, Billotcy C, Meyer P, Barbel J, Milhaud G: Radio-imniunoguided surgery of very' small CEA expressing metastascs (2 mm in diameter) using a bispecific antibody and bivalent haptens (abstract), 42th Annu Meet SNM, Minneapolis, 1995.
21. 111 l-labclcd bivalent hapten in patients with medullary thyroid carcinoma and small-cell lung cancer, J Nucl Med 1996:37: 1853-1859.
22. Juweid M, Sharkey RM, Behr T, Swayne LC, Rubin AD, Herskovic T, Hanley D, Markowitz A, Dunn R, Siegel J, Kamal T, Goldenberg DM: Improved detection of medullary thyroid cancer with radiolabeled antibodies to carci-noembryonic antigen, J Clin Oncol 1996:14: 1209-1217.
23. Tiscll LE, Hansson G, Jansson S, Salander H: Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma, Surgery 1986;99:60-66.
24. Moley JF, Wells SA, Dilley WG, Tisell LE: Rcoperation for recurrent or persistent medullary thyroid cancer, Surgerv 1993; 114:1090-1095
25. Buhr HJ, Kallinowski F, Rauc F, Frank-Rauc K, Herfarth C: Microsurgical neck dissection for occultly metastasizing medullary thyroid carcinoma, Three-year results, Canccr 1993: 72:3685-3693.
26. Buhr HJ, Kallinowski F, Rauc F, Frank-Raue K, Herfarth C: Microsurgical neck disscction for metastasizing medullary thyroid carcinoma, Eur J Surg Oncol 1995;21:195-197.
27. Wu LT, Avcrbuch SD, Ball DW, dc Bustros A, Baylin SB, McGuire WP III: Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazinc, Canccr 1994:73:432-436.
28. Schlumbcrgcr M, Abdclmoumene N, Delisle MJ, Couetle JE, Groupe d’Elude des Tumeurs a Calcitonine: Treatment of advanced medullary thyroid canccr with an alternating combination of 5FU-streptozocin and 5FU-dacarba-zine, Br J Canccr 1995:71:363-365.
29. mI-labeled monoclonal antibodies to carcinoembryonic antigen, Canccr Res 1995;55(suppl):5946-5951.
30. Juweid M, Sharkey RM, Behr T, Swayne LC, Herskovic T, Pereira M, Rubin AD, Hanley D, Dunn R, Siegel J, Goldenberg DM: Radioimmunotherapy of medullary' thyroid cancer with iodine-131-labclcd anti-CEA antibodies, J Nucl Med 1996:37:905-911.
31. Thomas SR, Maxon HR, Kerciakcs JG: In vivo quantitation of lesion radioactivity using external counting methods, Med Phys 1976:3:253-255.